Antisense K-ras RNA gene therapy - Silenseed

Drug Profile

Antisense K-ras RNA gene therapy - Silenseed

Alternative Names: siG12D LODER

Latest Information Update: 11 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Silenseed
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action KRAS protein modulators; Ras gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pancreatic cancer

Most Recent Events

  • 11 Jan 2016 siG12D-LODER is in phase IIa development for Pancreatic cancer in Israel
  • 04 Jun 2013 Adverse events and efficacy data from a phase I/II trial in Pancreatic cancer presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
  • 29 Aug 2012 Silenseed plans a phase II/III trial for Pancreatic cancer (locally-advanced, first-line therapy) in Israel (NCT01676259)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top